Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland
- 525 Downloads
FRAX-based cost-effective intervention thresholds in the Swiss setting were determined. Assuming a willingness to pay at 2× Gross Domestic Product per capita, an intervention aimed at reducing fracture risk in women and men with a 10-year probability for a major osteoporotic fracture at or above 15% is cost-effective.
The fracture risk assessment algorithm FRAX® has been recently calibrated for Switzerland. The aim of the present analysis was to determine FRAX-based fracture probabilities at which intervention becomes cost-effective.
A previously developed and validated state transition Markov cohort model was populated with Swiss epidemiological and cost input parameters. Cost-effective FRAX-based intervention thresholds (cost-effectiveness approach) and the cost-effectiveness of intervention with alendronate (original molecule) in subjects with a FRAX-based fracture risk equivalent to that of a woman with a prior fragility fracture and no other risk factor (translational approach) were calculated based on the Swiss FRAX model and assuming a willingness to pay of 2 times Gross Domestic Product per capita for one Quality-adjusted Life-Year.
In Swiss women and men aged 50 years and older, drug intervention aimed at decreasing fracture risk was cost-effective with a 10-year probability for a major osteoporotic fracture at or above 13.8% (range 10.8% to 15.0%) and 15.1% (range 9.9% to 19.9%), respectively. Age-dependent variations around these mean values were modest. Using the translational approach, treatment was cost-effective or cost-saving after the age 60 years in women and 55 in men who had previously sustained a fragility fracture. Using the latter approach leads to considerable underuse of the current potential for cost-effective interventions against fractures.
Using a FRAX-based intervention threshold of 15% for both women and men should permit cost-effective access to therapy to patients at high fracture probability based on clinical risk factors and thereby contribute to further reduce the growing burden of osteoporotic fractures in Switzerland.
KeywordsAlendronate Cost-effectiveness FRAX® Intervention thresholds Osteoporosis Switzerland 10-year fracture probability
- 5.Bundesamt für Statistik. Szenarien zur Bevölkerungsentwicklung der Schweiz 2005–2050. http://www.bfs.admin.ch/bfs/portal/de/index/news/publikationen.Document.83713.pdf. Last visited May 14, 2008.
- 7.(1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94(6):646–650Google Scholar
- 13.(2011) Bundesamt für Gesundheit (BAG). List of reimbursed medicines in Switzerland (Spezialitätenliste). http://www.sl.bag.admin.ch
- 15.Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822PubMedCrossRefGoogle Scholar
- 25.(2010) National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. http://www.nof.org/professionals/clinical-guidelines.
- 27.(1999) Royal College of Physicians. Osteoporosis: clinical guidelines for the prevention and treatment. London, Royal College of PhysiciansGoogle Scholar
- 28.(2010) Diagnostik, Prävention und Behandlung der Osteoporose: Empfehlungen der Schweizerischen Gesellschaft gegen Osteoporose (SVGO). http://www.svgo.ch/. Last visited August 8, 2011:
- 30.Kanis J (2007) World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. Technical report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK.Google Scholar
- 32.Krieg MA, Cornuz J, Ruffieux C et al (2006) Prediction of hip fracture risk by quantitative ultrasound in more than 7000 Swiss women > or =70 years of age: comparison of three technologically different bone ultrasound devices in the SEMOF study. J Bone Miner Res 21:1457–1463PubMedCrossRefGoogle Scholar
- 45.(2008) Life tables for WHO member states. Switzerland. <http://www.who.int/healthinfo/statistics/mortality_life_tables/en/> Accessed May 12, 2011.
- 49.Poor G, Atkinson EJ, O’Fallon WM, Melton LJ 3rd (1995) Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res (319):260–265Google Scholar
- 53.(2008) National Institute for Health and Clinical Excellence (NICE). Systematic reviews of clinical effectiveness prepared for the guideline ‘Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk’ http://www.nice.org.uk/nicemedia/live/11621/42362/42362.pdf. Last visited April18, 2011.
- 60.Lloyd Jones M, Wilkinson A (2006) Adverse effects and persistence with therapy in patients taking oral alendronate, etidronate or risedronate: a systematic review. NHS R & D HTA ScHARR. http://www.nice.org.uk/nicemedia/live/11680/36718/36718.pdf. Accessed May 12, 2011.
- 61.(2011) OECD Consumer Price Indices. Available from www.oecd.org/std/prices-indices. http://stats.oecd.org/Index.aspx?querytype=view&queryname=221. Accessed May 12, 2011.
- 64.Szucs TD, Hauselmann H (2000) Die Wirtschaftlichkeit von Alendronat in der Behandlung der postmenopausalen Osteoporose. Ökon Qual Manag 5:99–106Google Scholar
- 65.(2001) Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Available under http://whqlibdoc.who.int/publications/2001/924154550x.pdf. Last accessed October 4th, 2011. Geneva, World Health Organization
- 68.Swiss Federal Statistical Office (SFSO). Gross Domestic Product per capita. http://www.bfs.admin.ch/bfs/portal/de/index/themen/04/02/01/key/bip_einw.html. Last visited April 18th, 2011.
- 73.Kanis JA, Reginster JY, Kaufman JM, Ringe JD, Adachi JD, Hiligsmann M, Rizzoli R, Cooper C (2011) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int (in press)Google Scholar
- 78.McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, Jalava T, Kanis JA (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811–817PubMedCrossRefGoogle Scholar
- 81.McCloskey E, Lewiecki EM, Kanis JA et al (2011) Denosumab reduces the risk of clinical osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX®. Osteoporos Int 22(supplement 1):S103Google Scholar
- 82.Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2011) FRAX® with and without BMD. Calcif Tissue Int (in press)Google Scholar
- 83.Lippuner K, Popp AW, Schwab P, Gitlin M, Schaufler T, Senn C, Perrelet R (2010) Fracture hospitalizations between years 2000 and 2007 in Switzerland: a trend analysis. Osteoporos Int (in press)Google Scholar